On July 25, 2019 Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology to improve protein therapies for unmet patient needs, reported that it will report its financial results for the second quarter and six months ended June 30, 2019, after the market close on Thursday, August 8, 2019, and will host a conference call and webcast at 4:30 PM Eastern Time (Press release, Pfenex, JUL 25, 2019, View Source [SID1234538433]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Call & Webcast
Thursday, August 8th @ 4:30pm Eastern Time/1:30pm Pacific Time
Domestic:866-376-8058
International:412-542-4131
Webcast: View Source
Replays, Available Through August 15th:
Domestic:877-344-7529
International:412-317-0088
Replay Access Code:10133889
About Pfenex Inc.
P